Oculis Holding AG (OCS)

NASDAQ: OCS · Real-Time Price · USD
19.18
-0.22 (-1.13%)
At close: Mar 28, 2025, 4:00 PM
19.14
-0.04 (-0.21%)
After-hours: Mar 28, 2025, 4:55 PM EDT
-1.13%
Market Cap 1.02B
Revenue (ttm) 757,024
Net Income (ttm) -94.66M
Shares Out 52.94M
EPS (ttm) -2.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 35,276
Open 19.45
Previous Close 19.40
Day's Range 19.00 - 19.63
52-Week Range 10.55 - 23.08
Beta 0.05
Analysts Strong Buy
Price Target 29.50 (+53.81%)
Earnings Date Mar 11, 2025

About OCS

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneratio... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 49
Stock Exchange NASDAQ
Ticker Symbol OCS
Full Company Profile

Financial Performance

In 2024, Oculis Holding AG's revenue was 686,000, a decrease of -22.31% compared to the previous year's 883,000. Losses were -85.78 million, -3.41% less than in 2023.

Financial numbers in CHF Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price forecast is $29.5, which is an increase of 53.81% from the latest price.

Price Target
$29.5
(53.81% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1...

10 days ago - GlobeNewsWire

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as purcha...

16 days ago - GlobeNewsWire

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophth...

19 days ago - GlobeNewsWire

Oculis to Present at Upcoming March Investor Conference

ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care...

25 days ago - GlobeNewsWire

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthal...

6 weeks ago - GlobeNewsWire

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.

7 weeks ago - GlobeNewsWire

Oculis updates share capital for its existing at-the-market offering program

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of...

2 months ago - GlobeNewsWire

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS...

2 months ago - Seeking Alpha

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Cla...

2 months ago - GlobeNewsWire

Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities

ZUG, Nov. 27, 2024 (GLOBE NEWSWIRE) -- The attached notification relates to a one-time equity incentive award issued to a director of the Company for his independent services as a consultant to the Co...

4 months ago - GlobeNewsWire

Oculis to Present at the Stifel 2024 Healthcare Conference

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...

4 months ago - GlobeNewsWire

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and imp...

5 months ago - GlobeNewsWire

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...

5 months ago - GlobeNewsWire

Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...

5 months ago - GlobeNewsWire

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune r...

Other symbols: ENTOONCOVRNA
6 months ago - Business Wire

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...

6 months ago - GlobeNewsWire

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collabora...

6 months ago - GlobeNewsWire

Oculis to Present at Upcoming September Investor Conferences

ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...

7 months ago - GlobeNewsWire

Oculis Publishes Consolidated Q2 Financial Statements and MD&A

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Following the Company‘s press release published earlier today, the Q2 Consolidated Financial Statements and the MD&A, which have now been filed with...

7 months ago - GlobeNewsWire

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and imp...

7 months ago - GlobeNewsWire

Oculis Reports Q2 Financial Results and Provides Recent Company Update

ZUG, Switzerland, Aug. 27, 2024 (GLOBE NEWSWIRE) --   Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and i...

7 months ago - GlobeNewsWire

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...

8 months ago - GlobeNewsWire

Oculis and EURETINA Announces the Ramin Tadayoni Award

ZUG, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and imp...

9 months ago - GlobeNewsWire

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

ZUG, Switzerland, June 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announc...

10 months ago - GlobeNewsWire

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and impr...

10 months ago - GlobeNewsWire